Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020;2(9):1323-1327.
doi: 10.1007/s42399-020-00409-7. Epub 2020 Jul 23.

Investigation of Anti-SARS-CoV-2 IgG and IgM Antibodies in the Patients with COVID-19 by Three Different ELISA Test Kits

Masayuki Nagasawa  1   2 , Yoshimi Yamaguchi  3 , Maki Furuya  3 , Yui Takahashi  3 , Reiko Taki  4 , Kaoru Nagata  5 , Shinichiro Suzaki  6 , Masayuki Kurosaki  7 , Namiki Izumi  8
Affiliations

Investigation of Anti-SARS-CoV-2 IgG and IgM Antibodies in the Patients with COVID-19 by Three Different ELISA Test Kits

Masayuki Nagasawa et al. SN Compr Clin Med. 2020.

Abstract

We examined anti-SARS-CoV-2 IgG and IgM antibodies in 45 serum samples from 26 patients with COVID-19, who were admitted in our hospital by using three different ELISA kits. All patients had pneumonia at admission, and 7 patients required mechanical ventilator support and grouped in severe case. Anti-SARS-CoV-2 IgG and IgM antibodies turned to be partially positive between the 6th and 10th days, more than 84% positive between the 11th and 15th days, and 100% after the 16th day. One ELISA kit revealed poorer sensitivity for anti-SARS-CoV-2 IgM antibody. Negative conversion of IgM antibody was not observed in the 30th day in our cohort. All three ELISA kits showed no false positive reaction for negative serum samples. Between severe and moderate cases, there was no significant difference in the trends of anti-SARS-CoV-2 IgG and IgM antibody.

Keywords: Antibody; COVID-19; ELISA; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Conflict of InterestThe authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
The trends of anti-SARS-CoV-2 IgG and IgM antibodies detected by three different ELISA kits
Fig. 2
Fig. 2
Comparison of the trends of anti-SARS-CoV-2 IgG and IgM antibodies between severe and moderate cases
See this image and copyright information in PMC

References

    1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus Investigating and Research Team A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi: 10.1056/NEJMoa2001017. - DOI - PMC - PubMed
    1. World Health Organization Coronavirus disease (COVID-19). Situation report–140. https://wwwwhoint/docs/default-source/coronaviruse/situation-reports/20200608-covid-19-sitrep-140pdf/sfvrsn=2f310900_2 (accessed, June 9, 2020).
    1. Zhang L, Pang R, Xue X, Bao J, Ye S, Dai Y, et al. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. Aging (Albany NY). 2020;12 Epub 2020/04/23. eng. - PMC - PubMed
    1. Xiang F, Wang X, He X, Peng Z, Yang B, Zhang J, et al. Antibody detection and dynamic characteristics in patients with COVID-19. Clin Infect Dis. 2020;19 Epub 2020/04/20. eng. - PMC - PubMed
    1. Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, et al. Evaluation of nucleocapsid and spike protein-based ELISAs for detecting antibodies against SARS-CoV-2. J Clin Microbiol. 2020;30 Epub 2020/04/02. eng. - PMC - PubMed

LinkOut - more resources